Iradimed
IRMD
Iradimed (IRMD) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.46
- EPS estimate
- $0.44
- EPS surprise
- +4.55%
- Revenue surprise
- +0.57%
- Revenue
- $20.5M
- Revenue estimate
- $20.4M
- Reported
- Jul 31, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 31, 2026 | $0.44 | $0.46 | +4.55% | $20.5M | SEC |
| Q1 2026 | May 1, 2026 | $0.45 | $0.49 | +10.11% | $22.0M | SEC |
| Q4 2025 | Feb 10, 2026 | $0.48 | $0.54 | +12.50% | $22.7M | SEC |
| Q3 2025 | Nov 3, 2025 | $0.46 | $0.47 | +3.30% | $21.2M | SEC |
| Q2 2025 | Aug 1, 2025 | $0.44 | $0.49 | +12.64% | $20.4M | SEC |
| Q1 2025 | May 5, 2025 | $0.41 | $0.42 | +2.44% | $19.5M | SEC |
| Q4 2024 | Feb 13, 2025 | $0.44 | $0.44 | +0.00% | $19.4M | SEC |
| Q3 2024 | Oct 31, 2024 | $0.41 | $0.43 | +6.17% | $18.3M | SEC |
| Q2 2024 | Aug 1, 2024 | $0.37 | $0.42 | +15.07% | $17.9M | SEC |
| Q1 2024 | May 2, 2024 | $0.34 | $0.36 | +7.46% | $17.6M | SEC |
| Q4 2023 | Feb 8, 2024 | $0.38 | $0.39 | +2.63% | $17.5M | SEC |
| Q3 2023 | Nov 3, 2023 | $0.36 | $0.43 | +18.36% | $16.5M | SEC |
| Q2 2023 | Aug 3, 2023 | $0.31 | $0.36 | +16.13% | $16.1M | SEC |
| Q1 2023 | May 4, 2023 | $0.28 | $0.30 | +5.89% | $15.5M | SEC |
| Q4 2022 | Feb 2, 2023 | $0.30 | $0.32 | +6.67% | $14.9M | SEC |
| Q3 2022 | Nov 3, 2022 | $0.25 | $0.29 | +18.37% | $13.4M | — |
| Q2 2022 | Jul 29, 2022 | $0.24 | $0.26 | +10.64% | $12.7M | — |
| Q1 2022 | Apr 29, 2022 | $0.21 | $0.22 | +4.76% | $12.3M | — |
| Q4 2021 | Feb 4, 2022 | $0.20 | $0.33 | +69.23% | $11.9M | — |
| Q3 2021 | Oct 29, 2021 | $0.17 | $0.23 | +35.29% | $10.9M | — |
Quarterly revenue
Frequently asked questions
When did Iradimed (IRMD) last report earnings?
Iradimed last reported on Jul 31, 2026, covering fiscal Q2 2026.
Did IRMD beat earnings estimates?
Yes. Iradimed reported EPS of $0.46 for Q2 2026 against a $0.44 estimate — a 4.55% beat.
How much revenue did IRMD report last quarter?
Iradimed reported $20.5M in revenue for Q2 2026, against a consensus estimate of $20.4M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.